source
- Daraxonrasib shows promising pancreatic cancer results as Chinese lung therapy exceeds expectationsThe latest ASCO updates highlighted detailed data on daraxonrasib, a drug targeting pancreatic cancer, indicating encouraging efficacy signals for patients. In parallel, a lung cancer treatment de…
- Servier acquires Edgewise's muscular dystrophy assets for $1.55 billionServier announced it will purchase the muscular dystrophy business from Edgewise Therapeutics. The deal involves an upfront payment of $1.55 billion, giving the French company rights to Edgewise's…